Renal Anemia | Treatment Algorithms: Claims Data Analysis | US | 2025

Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal anemia treatment is to increase and maintain Hb levels and reduce the risk of complications of chronic hypoxia, mortality, and cardiovascular disease. The severity of CKD and Hb levels dictate the choice of renal anemia therapy. Renal anemia nondialysis patients are initially treated with oral iron, followed by IV iron; ESAs are prescribed as third-line therapy. Dialysis patients usually receive IV iron therapy and ESAs, with HIF-PH inhibitors prescribed as third-line therapy, primarily for ESA-resistant patients. Several ESAs and iron supplements are available, with varying degrees of commercial success. This report provides important insights into how these agents are used in the management of renal anemia and how practices are evolving.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed renal anemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed renal anemia patients?
• How have HIF-PH inhibitors been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of renal anemia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of renal anemia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Markets covered: United States

Key companies: Amgen, Johnson & Johnson Innovative Medicine, Pfizer, Roche, Teva, GlaxoSmithKline, Akebia Therapeutics

Key drugs: Short-acting ESAs, long-acting ESAs, HIF-PH inhibitors, iron supplements

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.